The Eliquis update in #msg-87309873 comes from yesterday's BMY CC. This is consequential info insofar as the Eliquis program in VTE prevention has been retarded in the US compared to the EU, where Eliquis received approval in 2011.
The AMPLIFY phase-3 study, which will determine whether BMY/PFE submit an sNDA for Eliquis in VTE treatment, is described in #msg-29928836.
[Please keep these entries up to date! See the updating procedure at the end of this post. Items that are out of date will be removed.]
NOTE: ANYONE MAY UPDATE THIS FILE
Edits: GILD (FDA issues CRL for Elvitegravir, Cobicstat NDAs).
ABT – ‘Absorb’ bioresorbable stent: US launch possible in 2013, pending clinical results. (Launched in 30 countries including EU 9/25/12.)
AGN – Phase-2 DARPin data in AMD: 2H13. AGN – Latisse for androgenetic alopecia: phase-2 data in men and women at unspecified medical conference in 2013. AGN – PMA for Juvederm Voluma: PDUFA date 1H13.
AMGN – Xgeva sBLA submission for bone health in non-metastatic cancer: 2013 pending results of phase-3 trial in breast cancer.
AMRN – Vascepa (f/k/a AMR101) approved by FDA 7/26/12; decision on NCE status pending.
BAX – Gammagard in AD 1st ph3: top-line results 2Q13, full dataset Jul 2013. Gammagard in AD 2nd ph3: complete enrollment end 2013, results 2015.
BMY – Eliquis: see PFE.
BMY – Yervoy phase-3 in 2nd-line CRPC: data mid 2013.
GILD –‘Quad Prime’ based on TAF (f/k/a GS-7340): Data from two phase-2 studies early 2013—one tests Quad Prime vs Atripla and one tests Quad Prime vs Prezista + Cobicstat + Truvada. (Ph2 testing Quad Prime vs Stribild reported 10/31/12.) GILD – “Standalone” Evitegravir NDA: FDA issued CRL on 4/29/13; no further details available. (Note: Evitegravir is one of the component drugs in Stribild.) GILD – “Standalone” Cobicstat NDA: FDA issued CRL on 4/29/13; no further details available. MAA submitted 5/23/12; no further info available. (Note: Cobicstat is one of the component drugs in Stribild.)
IDIX – IDX719 (NS5A inhibitor, now IDIX’s lead drug): 3-day PoC phase-1b monotherapy data reported 6/20/12.
ITMN – Pirfenidone: No specific timeline for response to FDA’s CRL of 5/4/10 requesting a new trial.
JNJ – Xarelto sNDA in PCI sub-indication of ACS: PDUFA date should have been in Mar 2013 (sNDA resubmitted 9/7/12).
LGND - Promacta for HCV: EU MAA submitted 5/30/12. (Approved by FDA 11/19/12.)
PFE – Eliquis: sNDA in VTE prevention 3Q13; sNDA in VTE treatment late 2013 pending outcome of AMPLIFY study, which will be presented at ISTH in Jun 2013. (Eliquis was approved for VTE prevention in EU in 2011.)
SNY – Aubagio for RRMS: MAA accepted for review 2/23/12; (approved by FDA 9/12/12). Lemtrada for RRMS: RTF issued 8/27/12; resubmission pending.
TEVA – Thrice-weekly formulation of Copaxone: timing of NDA unclear according to 6/14/12 PR announcing positive top-line results from GALA study.
VRTX – Phase-2b testing multiple (non-response-guided) protocols for Incivek + VX-222 + ribavirin in treatment-naïve genotype-1 to start 3Q12. (Data on no-IFN arms of ZENITH study reported 2/23/12.)
XOMA – Data readouts from EYEGUARD-A/B/C phase-3 studies in uveitis: A (active NIU) end 2013; B (Behçet’s) mid 2014; C (maintenance NIU) 1Q14.
-- Procedure for Updating Calendar
When adding or modifying entries, please follow these steps:
1. Copy the complete text from the old calendar.
2. Make your additions or modifications, inserting new items in alphabetical order.
3. Near the top of the message, list the ticker symbols of the entries you changed (e.g. “Edits: GILD MNTA”).
Market Data 
Markets 
AI
